NovoCure Corp - NVCR Net earnings per one share for the last twelve months

Novocure (NVCR) - corporate logo

NovoCure Limited (NVCR) is diversifying its risks by implementing innovations to combat lung and brain tumors. However, geopolitical conflicts and sanctions are complicating device logistics and international trials. The net income per share YoY ttm growth rate chart visualizes profit dynamics, where the 34.10 level captures the current state. Patents for electric field technology form the business foundation, creating an insurmountable barrier for competitors.

NovoCure Limited (NVCR): Net earnings per share for the last 12 months from 02/11/2024 to 11/18/2026

Financial and market metric breakdowns for NovoCure Limited (NVCR)

- share price and consensus valuation forecast:
Initial company analysis:NVCR, NovoCure Ltd
Original product of Novocure

To minimize fundamental risks, investors should select assets with sustainable positive earnings momentum, where the 12-month annual growth in earnings per share measures the rate of change in net income per share relative to the same period last year. For NovoCure Limited (NVCR), this indicator reflects the commercialization efficiency of the Optune system and the expansion of insurance coverage amid expected FDA approvals.